Euro Area services are currently a key driver of growth, with tourism and external demand helping to keep activity ticking over. In that backdrop, investors are paying closer attention to companies where analysts see solid earnings growth potential and balance sheets that look reasonable. This article highlights three stocks from a Healthy high growth potential screener that meet those tests and could merit a spot on your watchlist.

The stocks discussed below are just a starting sample, and the full screen surfaced 282 more companies with similarly compelling growth and financial profiles that are not covered in this article. If you want to quickly identify your own highest conviction ideas, head straight into the Healthy high growth potential screener.

TOYO (TOYO)

Overview: TOYO Co., Ltd. is a Tokyo based solar manufacturer that designs, produces and sells wafers, cells and photovoltaic modules across Asia and the United States, giving it direct exposure to the solar power market that underpins the Healthy high growth potential screener. The company’s focus on the full solar value chain aligns its earnings outlook with demand for utility scale and other solar projects rather than more peripheral activities.

Operations: TOYO generates about US$549 million in revenue from Machinery & Industrial Equipment, with roughly US$469 million from the USA and the balance from other regions.

Market Cap: US$206 million

Investors looking at TOYO are getting a pure play on solar cells and PV modules through capacity ramps in Ethiopia and Houston and long term supply deals with U.S. developers. Return on equity is strong and margins have been improving, which together help explain why the stock screens well for quality growth. At the same time, heavy reliance on external borrowing, fast growing operating expenses and ongoing trade policy reviews introduce real execution and funding risk. For growth focused investors, the question is whether TOYO’s policy aligned U.S. build out and lower cost manufacturing base can outweigh those pressures over the next few years.

TOYO’s full value chain solar story and improving margins suggest that there is more going on beneath the headline numbers. Get the context on funding pressure and quality metrics in the 4 key rewards and 1 important major warning sign

Build your own high growth solar shortlist

TOYO and the two other stocks in this article all came from a single screener, which shows how powerful targeted filters can be when you are looking for growth backed by reasonable balance sheets. Use our flexible Screener to combine your preferred metrics, or use our curated Investing Ideas if you prefer ready made starting points.

Amylyx Pharmaceuticals (AMLX)

Overview: Amylyx Pharmaceuticals is a Cambridge based clinical stage company focused on treatments for neurodegenerative and rare endocrine diseases, with AMX0114 for amyotrophic lateral sclerosis and AMX0035 for progressive supranuclear palsy forming the clearest link to the Healthy high growth potential theme through late stage development work that could reshape its earnings profile if trials and approvals succeed. Alongside these programs, Amylyx is advancing avexitide and other GLP 1 receptor antagonists for post bariatric hypoglycemia and related conditions, which broadens its potential revenue base without changing the fact that future growth rests on converting this pipeline into approved therapies.

Market Cap: US$4.3b

Investors watching Amylyx Pharmaceuticals are seeing a company at the point where clinical data is starting to bridge into a commercial story, helped by strong Phase 3 LUCIDITY results for avexitide in post bariatric hypoglycemia and recent funding of roughly US$350 million to US$500 million to support launch preparation and ongoing research. At the same time, Amylyx still reports losses of about US$150.1 million and depends on unproven assets like AMX0114 and AMX0035 in areas with high regulatory and execution risk, so success is far from assured. The interest lies in whether this mix of de risked PBH data, a multi asset neuro and endocrine pipeline and a strengthened balance sheet can justify current growth expectations over the next few years.

Amylyx Pharmaceuticals sits at a crossroads where late stage data and fresh funding could reshape the story. Get the full context in the 2 key rewards and 4 important warning signs (2 are major!)

MercadoLibre (MELI)

Overview: MercadoLibre is a Montevideo based company that runs one of Latin America’s largest online commerce platforms alongside Mercado Pago, a fintech ecosystem that offers digital payments, consumer and merchant lending through Mercado Crédito, and investment products via Mercado Fondo. While the marketplace still brings in a large share of revenue, the fastest connection to the Healthy high growth potential screener comes from Mercado Pago’s higher margin financial services, which are designed to lift earnings as adoption of digital finance accelerates across Brazil, Mexico, Argentina and other markets.

Operations: MercadoLibre generates about US$35.2b in revenue from Internet Software & Services, with key markets including Brazil at roughly US$19.0b, Mexico at about US$8.1b, Argentina at around US$6.6b and other countries contributing about US$1.6b.

Market Cap: US$97.5b

MercadoLibre offers a combination of a scaled e commerce platform and a fast growing fintech engine in Mercado Pago, which is central to the Healthy high growth potential theme. Analysts expect earnings to grow faster than revenue as higher margin payments, credit and investment products expand. Forecast earnings growth of roughly 29% a year and projected ROE above 30% sit alongside a stock price that is estimated to be well below fair value. At the same time, the company currently reports a 5.3% net margin and a business model that leans on external borrowing rather than customer deposits. The key question for investors is whether this funding approach and recent margin pressure are a temporary cost of building a Latin American fintech leader or a sign that the path to those forecasts may involve more volatility than headline growth figures indicate.

MercadoLibre’s fintech engine and e commerce scale are often viewed in isolation. The real story sits in how payments growth, funding choices and margin pressure interact. Get the analyst forecasts for MercadoLibre and see what the headline numbers might be hiding.

Seeking Fresh Alternatives Before Others Do

Fresh opportunities do not stay quiet for long. Strong stories move from under the radar to fully priced as momentum builds. Scan these ideas before the crowd and consider your options.

• Spot resilient compounders early by running a tight filter on quality and risk using the curated 77 resilient stocks with low risk scores while prices still reflect cautious expectations.
• Explore the breakout potential in infrastructure and grid upgrades through the hand picked companies inside the 39 power grid technology and infrastructure stocks before capital flows broaden.
• Screen for potential AI build out enablers in chips, data centers and networking through the focused 55 AI infrastructure stocks while the theme is still developing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.